Bibliography
At KinN Therapeutics we value high-quality research that stands up to peer review. We have enjoyed many collaborations that have resulted in publications. Below is a comprehensive list of publications our team members have contributed to over the past decade. Publications have been placed into the most relevant category however many could fit into multiple sections.
Xenograft & Imaging
Perrone MG, Vitale P, Miciaccia M, Ferorelli S, Centonze A, Solidoro R, Munzone C, Bonaccorso C, Fortuna CG, Kleinmanns K, Bjørge L, Scilimati A. Fluorochrome Selection for Imaging Intraoperative Ovarian Cancer Probes. Pharmaceuticals (Basel). 2022; 15(6). Epub 20220526. doi: 10.3390/ph15060668. PubMed PMID: 35745587; PubMed Central PMCID: PMC9230671; https://www.ncbi.nlm.nih.gov/pubmed/35745587
Popa M, Fosse V, Kleinmanns K, Bjørge L, McCormack E. Xenograft Models of Ovarian Cancer for Therapy Evaluation. In: Kreeger PK, editor. Ovarian Cancer: Methods and Protocols. New York, NY: Springer US; 2022. p. 275-93. https://doi.org/10.1007/978-1-0716-1956-8_18
Berg HF, Hjelmeland ME, Lien H, Espedal H, Fonnes T, Srivastava A, Stokowy T, Strand E, Bozickovic O, Stefansson IM, Bjørge L, Trovik J, Haldorsen IS, Hoivik EA, Krakstad C. Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis. Commun Med (Lond). 2021; 1:20. Epub 20210730. doi: 10.1038/s43856-021-00019-x. PubMed PMID: 35602206; PubMed Central PMCID: PMC9053236; https://www.ncbi.nlm.nih.gov/pubmed/35602206
García de Jalón E, Kleinmanns K, Fosse V, Davidson B, Bjørge L, Haug BE, McCormack E. Comparison of Five Near-Infrared Fluorescent Folate Conjugates in an Ovarian Cancer Model. Mol Imaging Biol. 2021. Epub 20211210. doi: 10.1007/s11307-021-01685-y. PubMed PMID: 34888759; https://www.ncbi.nlm.nih.gov/pubmed/34888759
Shafiee S, Gelebart P, Popa M, Hellesøy M, Hovland R, Brendsdal Forthun R, Lee J, Tohyama K, Molven A, Parekkadan B, Tore Gjertsen B, Olsnes Kittang A, McCormack E. Preclinical characterisation and development of a novel myelodysplastic syndrome-derived cell line. Br J Haematol. 2021; 193(2):415-9. Epub 20210309. doi: 10.1111/bjh.17372. PubMed PMID: 33686650; PubMed Central PMCID: PMC8112349; https://www.ncbi.nlm.nih.gov/pubmed/33686650
Fonnes T, Strand E, Fasmer KE, Berg HF, Espedal H, Sortland K, Stefansson I, Bjørge L, Haldorsen IS, Krakstad C, McCormack E. Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. Cancers (Basel). 2020; 12(2). Epub 20200206. doi: 10.3390/cancers12020370. PubMed PMID: 32041116; PubMed Central PMCID: PMC7072497; https://www.ncbi.nlm.nih.gov/pubmed/32041116
Kleinmanns K, Bischof K, Anandan S, Popa M, Akslen LA, Fosse V, Karlsen IT, Gjertsen BT, Bjørge L, McCormack E. CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. EBioMedicine. 2020; 56:102782. Epub 20200523. doi: 10.1016/j.ebiom.2020.102782. PubMed PMID: 32454401; PubMed Central PMCID: PMC7248428; https://www.ncbi.nlm.nih.gov/pubmed/32454401
Kleinmanns K, Fosse V, Davidson B, García de Jalón E, Tenstad O, Bjørge L, McCormack E. CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model. EBioMedicine. 2020; 56:102783. Epub 20200523. doi: 10.1016/j.ebiom.2020.102783. PubMed PMID: 32454402; PubMed Central PMCID: PMC7248677; https://www.ncbi.nlm.nih.gov/pubmed/32454402
Omsland M, Andresen V, Gullaksen SE, Ayuda-Duran P, Popa M, Hovland R, Brendehaug A, Enserink J, McCormack E, Gjertsen BT. Tyrosine kinase inhibitors and interferon-alpha increase tunneling nanotube (TNT) formation and cell adhesion in chronic myeloid leukemia (CML) cell lines. FASEB J. 2020; 34(3):3773-91. Epub 20200116. doi: 10.1096/fj.201802061RR. PubMed PMID: 31945226; https://www.ncbi.nlm.nih.gov/pubmed/31945226
Gras Navarro A, Espedal H, Joseph JV, Trachsel-Moncho L, Bahador M, Gjertsen BT, Kristoffersen EK, Simonsen A, Miletic H, Enger PO, Rahman MA, Chekenya M. Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival. Cancers (Basel). 2019; 11(7). Epub 20190717. doi: 10.3390/cancers11070996. PubMed PMID: 31319548; PubMed Central PMCID: PMC6678126; https://www.ncbi.nlm.nih.gov/pubmed/31319548
Hanes R, Munthe E, Grad I, Han J, Karlsen I, McCormack E, Meza-Zepeda LA, Stratford EW, Myklebost O. Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma. Cells. 2019; 8(2):189. Epub 20190221. doi: 10.3390/cells8020189. PubMed PMID: 30795553; PubMed Central PMCID: PMC6406403; https://www.ncbi.nlm.nih.gov/pubmed/30795553
Rahman MA, Gras Navarro A, Brekke J, Engelsen A, Bindesboll C, Sarowar S, Bahador M, Bifulco E, Goplen D, Waha A, Lie SA, Gjertsen BT, Selheim F, Enger PO, Simonsen A, et al. Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival. Br J Cancer. 2019; 121(7):545-55. Epub 20190815. doi: 10.1038/s41416-019-0551-1. PubMed PMID: 31413318; PubMed Central PMCID: PMC6888814; https://www.ncbi.nlm.nih.gov/pubmed/31413318
Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, Yadav B, Tamborero D, Tang J, Bychkov D, Kontro M, Parsons A, Suvela M, Mayoral Safont M, Porkka K, et al. JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood. 2017; 130(6):789-802. Epub 20170615. doi: 10.1182/blood-2016-02-699363. PubMed PMID: 28619982; https://www.ncbi.nlm.nih.gov/pubmed/28619982
Andresen V, Erikstein BS, Mukherjee H, Sulen A, Popa M, Sornes S, Reikvam H, Chan KP, Hovland R, McCormack E, Bruserud Ø, Myers AG, Gjertsen BT. Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death Dis. 2016; 7(12):e2497. Epub 20161201. doi: 10.1038/cddis.2016.392. PubMed PMID: 27906185; PubMed Central PMCID: PMC5260983; https://www.ncbi.nlm.nih.gov/pubmed/27906185
Gelebart P, Popa M, McCormack E. Xenograft Models of Primary Acute Myeloid Leukemia for the Development of Imaging Strategies and Evaluation of Novel Targeted Therapies. Curr Pharm Biotechnol. 2016; 17(1):42-51. doi: 10.2174/1389201016666150817095703. PubMed PMID: 26278528; https://www.ncbi.nlm.nih.gov/pubmed/26278528
Helland Ø, Popa M, Bischof K, Gjertsen BT, McCormack E, Bjørge L. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer. PLoS One. 2016; 11(6):e0158208. Epub 20160628. doi: 10.1371/journal.pone.0158208. PubMed PMID: 27352023; PubMed Central PMCID: PMC4924861; https://www.ncbi.nlm.nih.gov/pubmed/27352023
Leitch C, Osdal T, Andresen V, Molland M, Kristiansen S, Nguyen XN, Bruserud Ø, Gjertsen BT, McCormack E. Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia. Oncotarget. 2016; 7(7):8105-18. doi: 10.18632/oncotarget.6991. PubMed PMID: 26812881; PubMed Central PMCID: PMC4884979; https://www.ncbi.nlm.nih.gov/pubmed/26812881
Haldorsen IS, Popa M, Fonnes T, Brekke N, Kopperud R, Visser NC, Rygh CB, Pavlin T, Salvesen HB, McCormack E, Krakstad C. Multimodal Imaging of Orthotopic Mouse Model of Endometrial Carcinoma. PLoS One. 2015; 10(8):e0135220. Epub 20150807. doi: 10.1371/journal.pone.0135220. PubMed PMID: 26252891; PubMed Central PMCID: PMC4529312; https://www.ncbi.nlm.nih.gov/pubmed/26252891
Hampson P, Wang K, Ersvaer E, McCormack E, Schuler J, Fiebig HH, Gjertsen BT, Bruserud Ø, Lord JM. Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound PEP005 in primary AML cells. Oncoscience. 2014; 1(8):529-39. Epub 20140806. doi: 10.18632/oncoscience.71. PubMed PMID: 25594060; PubMed Central PMCID: PMC4278328; https://www.ncbi.nlm.nih.gov/pubmed/25594060
Helland Ø, Popa M, Vintermyr OK, Molven A, Gjertsen BT, Bjørge L, McCormack E. First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma. PLoS One. 2014; 9(3):e89527. Epub 20140304. doi: 10.1371/journal.pone.0089527. PubMed PMID: 24594904; PubMed Central PMCID: PMC3942384; https://www.ncbi.nlm.nih.gov/pubmed/24594904
Jarzabek MA, Huszthy PC, Skaftnesmo KO, McCormack E, Dicker P, Prehn JH, Bjerkvig R, Byrne AT. In vivo bioluminescence imaging validation of a human biopsy-derived orthotopic mouse model of glioblastoma multiforme. Mol Imaging. 2013; 12(3):161-72. PubMed PMID: 23490442; https://www.ncbi.nlm.nih.gov/pubmed/23490442
McCormack E, Adams KJ, Hassan NJ, Kotian A, Lissin NM, Sami M, Mujić M, Osdal T, Gjertsen BT, Baker D, Powlesland AS, Aleksic M, Vuidepot A, Morteau O, Sutton DH, et al. Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1- and LAGE-1-positive tumors. Cancer Immunol Immunother. 2013; 62(4):773-85. Epub 20121222. doi: 10.1007/s00262-012-1384-4. PubMed PMID: 23263452; PubMed Central PMCID: PMC3624013; https://www.ncbi.nlm.nih.gov/pubmed/23263452
McCormack E, Mujić M, Osdal T, Bruserud Ø, Gjertsen BT. Multiplexed mAbs: a new strategy in preclinical time-domain imaging of acute myeloid leukemia. Blood. 2013; 121(7):e34-42. Epub 20121212. doi: 10.1182/blood-2012-05-429555. PubMed PMID: 23243270; https://www.ncbi.nlm.nih.gov/pubmed/23243270
Qu Y, Li WC, Hellem MR, Rostad K, Popa M, McCormack E, Oyan AM, Kalland KH, Ke XS. MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells. Int J Cancer. 2013; 133(3):544-55. Epub 20130227. doi: 10.1002/ijc.28056. PubMed PMID: 23354685; https://www.ncbi.nlm.nih.gov/pubmed/23354685
Qu Y, Oyan AM, Liu R, Hua Y, Zhang J, Hovland R, Popa M, Liu X, Brokstad KA, Simon R, Molven A, Lin B, Zhang WD, McCormack E, Kalland KH, et al. Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling. Cancer Res. 2013; 73(23):7090-100. Epub 20131007. doi: 10.1158/0008-5472.CAN-13-1560. PubMed PMID: 24101153; https://www.ncbi.nlm.nih.gov/pubmed/24101153
Lee J, Li M, Milwid J, Dunham J, Vinegoni C, Gorbatov R, Iwamoto Y, Wang F, Shen K, Hatfield K, Enger M, Shafiee S, McCormack E, Ebert BL, Weissleder R, et al. Implantable microenvironments to attract hematopoietic stem/cancer cells. Proc Natl Acad Sci U S A. 2012; 109(48):19638-43. Epub 20121112. doi: 10.1073/pnas.1208384109. PubMed PMID: 23150542; PubMed Central PMCID: PMC3511730; https://www.ncbi.nlm.nih.gov/pubmed/23150542
Xenograft & Imaging Mass Cytometry Theranostics Pharmacology AML
Mass Cytometry (CyTOF)
Kleinmanns K, Gullaksen SE, Bredholt G, Davidson B, Torkildsen CF, Grindheim S, Bjørge L, McCormack E. Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies. Cancers (Basel). 2022; 14(13):3092. Epub 20220623. doi: 10.3390/cancers14133092. PubMed PMID: 35804867; PubMed Central PMCID: PMC9265069; https://www.ncbi.nlm.nih.gov/pubmed/35804867
Liu XZ, Rulina A, Choi MH, Pedersen L, Lepland J, Takle ST, Madeleine N, Peters SD, Wogsland CE, Grondal SM, Lorens JB, Goodarzi H, Lonning PE, Knappskog S, Molven A, et al. C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer. Nat Commun. 2022; 13(1):69. Epub 20220110. doi: 10.1038/s41467-021-27734-2. PubMed PMID: 35013251; PubMed Central PMCID: PMC8748947; https://www.ncbi.nlm.nih.gov/pubmed/35013251
Anandan S, Thomsen LCV, Gullaksen SE, Abdelaal T, Kleinmanns K, Skavland J, Bredholt G, Gjertsen BT, McCormack E, Bjørge L. Phenotypic Characterization by Mass Cytometry of the Microenvironment in Ovarian Cancer and Impact of Tumor Dissociation Methods. Cancers (Basel). 2021; 13(4). Epub 20210211. doi: 10.3390/cancers13040755. PubMed PMID: 33670410; PubMed Central PMCID: PMC7918057; https://www.ncbi.nlm.nih.gov/pubmed/33670410
Wogsland CE, Lien HE, Pedersen L, Hanjra P, Grondal SM, Brekken RA, Lorens JB, Halberg N. High-dimensional immunotyping of tumors grown in obese and non-obese mice. Dis Model Mech. 2021; 14(4). Epub 20210330. doi: 10.1242/dmm.048977. PubMed PMID: 33653826; PubMed Central PMCID: PMC8033414; https://www.ncbi.nlm.nih.gov/pubmed/33653826
Fagerholt OHE, Hellesøy M, Gullaksen SE, Gjertsen BT. Single Cell Detection of the p53 Protein by Mass Cytometry. Cancers (Basel). 2020; 12(12). Epub 20201209. doi: 10.3390/cancers12123699. PubMed PMID: 33317179; PubMed Central PMCID: PMC7764694; https://www.ncbi.nlm.nih.gov/pubmed/33317179
Forthun RB, Hellesøy M, Sulen A, Kopperud RK, Sjoholt G, Bruserud Ø, McCormack E, Gjertsen BT. Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia. J Cancer Res Clin Oncol. 2019; 145(7):1729-49. Epub 20190520. doi: 10.1007/s00432-019-02931-1. PubMed PMID: 31111215; PubMed Central PMCID: PMC6571093; https://www.ncbi.nlm.nih.gov/pubmed/31111215
Gjertsen BT, Tislevoll BS, Fagerholt OHE, Hellesøy M. Early response evaluation in AML using mass cytometry. Hemasphere. 2019; 3(Suppl). Epub 20190630. doi: 10.1097/HS9.0000000000000215. PubMed PMID: 35309799; PubMed Central PMCID: PMC8925711; https://www.ncbi.nlm.nih.gov/pubmed/35309799
Gullaksen SE, Bader L, Hellesøy M, Sulen A, Fagerholt OHE, Engen CB, Skavland J, Gjertsen BT, Gavasso S. Titrating Complex Mass Cytometry Panels. Cytometry A. 2019; 95(7):792-6. Epub 20190409. doi: 10.1002/cyto.a.23751. PubMed PMID: 30964237; PubMed Central PMCID: PMC6766997; https://www.ncbi.nlm.nih.gov/pubmed/30964237
Huse K, Wogsland CE, Polikowsky HG, Diggins KE, Smeland EB, Myklebust JH, Irish JM. Human Germinal Center B Cells Differ from Naive and Memory B Cells in CD40 Expression and CD40L-Induced Signaling Response. Cytometry A. 2019; 95(4):442-9. Epub 20190305. doi: 10.1002/cyto.a.23737. PubMed PMID: 30838773; PubMed Central PMCID: PMC6711772; https://www.ncbi.nlm.nih.gov/pubmed/30838773
Diggins KE, Greenplate AR, Leelatian N, Wogsland CE, Irish JM. Characterizing cell subsets using marker enrichment modeling. Nat Methods. 2017; 14(3):275-8. Epub 20170130. doi: 10.1038/nmeth.4149. PubMed PMID: 28135256; PubMed Central PMCID: PMC5330853; https://www.ncbi.nlm.nih.gov/pubmed/28135256
Gullaksen SE, Skavland J, Gavasso S, Tosevski V, Warzocha K, Dumrese C, Ferrant A, Gedde-Dahl T, Hellmann A, Janssen J, Labar B, Lang A, Majeed W, Mihaylov G, Stentoft J, et al. Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib. Haematologica. 2017; 102(8):1361-7. Epub 20170518. doi: 10.3324/haematol.2017.167080. PubMed PMID: 28522574; PubMed Central PMCID: PMC5541871; https://www.ncbi.nlm.nih.gov/pubmed/28522574
Wogsland CE, Greenplate AR, Kolstad A, Myklebust JH, Irish JM, Huse K. Mass Cytometry of Follicular Lymphoma Tumors Reveals Intrinsic Heterogeneity in Proteins Including HLA-DR and a Deficit in Nonmalignant Plasmablast and Germinal Center B-Cell Populations. Cytometry B Clin Cytom. 2017; 92(1):79-87. doi: 10.1002/cyto.b.21498. PubMed PMID: 27933753; PubMed Central PMCID: PMC5506779; https://www.ncbi.nlm.nih.gov/pubmed/27933753
Sulen A, Gullaksen SE, Bader L, McClymont DW, Skavland J, Gavasso S, Gjertsen BT. Signaling effects of sodium hydrosulfide in healthy donor peripheral blood mononuclear cells. Pharmacol Res. 2016; 113(Pt A):216-27. Epub 20160816. doi: 10.1016/j.phrs.2016.08.018. PubMed PMID: 27543462; https://www.ncbi.nlm.nih.gov/pubmed/27543462
Polikowsky HG, Wogsland CE, Diggins KE, Huse K, Irish JM. Cutting Edge: Redox Signaling Hypersensitivity Distinguishes Human Germinal Center B Cells. J Immunol. 2015; 195(4):1364-7. Epub 20150708. doi: 10.4049/jimmunol.1500904. PubMed PMID: 26157177; PubMed Central PMCID: PMC4530023; https://www.ncbi.nlm.nih.gov/pubmed/26157177
Xenograft & Imaging Mass Cytometry Theranostics Pharmacology AML
Theranostics
Kotopoulis S, Popa M, Mayoral Safont M, Murvold E, Haugse R, Langer A, Dimcevski G, Lam C, Bjånes T, Gilja OH, McCormack E. SonoVue® vs. Sonazoid™ vs. Optison™: Which Bubble Is Best for Low-Intensity Sonoporation of Pancreatic Ductal Adenocarcinoma? Pharmaceutics. 2022; 14(1). Epub 20220101. doi: 10.3390/pharmaceutics14010098. PubMed PMID: 35056994; PubMed Central PMCID: PMC8777813; https://www.ncbi.nlm.nih.gov/pubmed/35056994
Eikrem O, Kotopoulis S, Popa M, Mayoral Safont M, Fossan KO, Leh S, Landolt L, Babickova J, Gudbrandsen OA, Gilja OH, Riedel B, Schjott J, McCormack E, Marti HP. Ultrasound and Microbubbles Enhance Uptake of Doxorubicin in Murine Kidneys. Pharmaceutics. 2021; 13(12). Epub 20211129. doi: 10.3390/pharmaceutics13122038. PubMed PMID: 34959319; PubMed Central PMCID: PMC8703523; https://www.ncbi.nlm.nih.gov/pubmed/34959319
Ruiz de Garibay G, García de Jalón E, Stigen E, Lund KB, Popa M, Davidson B, Safont MM, Rygh CB, Espedal H, Barrett TM, Haug BE, McCormack E. Repurposing 18F-FMISO as a PET tracer for translational imaging of nitroreductase-based gene directed enzyme prodrug therapy. Theranostics. 2021; 11(12):6044-57. Epub 20210407. doi: 10.7150/thno.55092. PubMed PMID: 33897898; PubMed Central PMCID: PMC8058731; https://www.ncbi.nlm.nih.gov/pubmed/33897898
Schultz CW, Ruiz de Garibay G, Langer A, Liu JB, Dhir T, Leitch C, Wessner CE, Mayoral M, Zhang B, Popa M, Huang C, Kotopoulis S, Luo X, Zhen Y, Niu S, et al. Selecting the optimal parameters for sonoporation of pancreatic cancer in a pre-clinical model. Cancer Biol Ther. 2021; 22(3):204-15. Epub 20210310. doi: 10.1080/15384047.2021.1881026. PubMed PMID: 33691611; PubMed Central PMCID: PMC8043187; https://www.ncbi.nlm.nih.gov/pubmed/33691611
Bjanes T, Kotopoulis S, Murvold ET, Kamceva T, Gjertsen BT, Gilja OH, Schjott J, Riedel B, McCormack E. Ultrasound- and Microbubble-Assisted Gemcitabine Delivery to Pancreatic Cancer Cells. Pharmaceutics. 2020; 12(2). Epub 20200207. doi: 10.3390/pharmaceutics12020141. PubMed PMID: 32046005; PubMed Central PMCID: PMC7076495; https://www.ncbi.nlm.nih.gov/pubmed/32046005
Haugse R, Langer A, Murvold ET, Costea DE, Gjertsen BT, Gilja OH, Kotopoulis S, Ruiz de Garibay G, McCormack E. Low-Intensity Sonoporation-Induced Intracellular Signalling of Pancreatic Cancer Cells, Fibroblasts and Endothelial Cells. Pharmaceutics. 2020; 12(11). Epub 20201106. doi: 10.3390/pharmaceutics12111058. PubMed PMID: 33171947; PubMed Central PMCID: PMC7694645; https://www.ncbi.nlm.nih.gov/pubmed/33171947
Kleinmanns K, Fosse V, Bjørge L, McCormack E. The Emerging Role of CD24 in Cancer Theranostics-A Novel Target for Fluorescence Image-Guided Surgery in Ovarian Cancer and Beyond. J Pers Med. 2020; 10(4). Epub 20201127. doi: 10.3390/jpm10040255. PubMed PMID: 33260974; PubMed Central PMCID: PMC7712410; https://www.ncbi.nlm.nih.gov/pubmed/33260974
Haugse R, Langer A, Gullaksen SE, Sundoy SM, Gjertsen BT, Kotopoulis S, McCormack E. Intracellular Signaling in Key Pathways Is Induced by Treatment with Ultrasound and Microbubbles in a Leukemia Cell Line, but Not in Healthy Peripheral Blood Mononuclear Cells. Pharmaceutics. 2019; 11(7). Epub 20190706. doi: 10.3390/pharmaceutics11070319. PubMed PMID: 31284599; PubMed Central PMCID: PMC6680714; https://www.ncbi.nlm.nih.gov/pubmed/31284599
Kotopoulis S, Stigen E, Popa M, Safont MM, Healey A, Kvale S, Sontum P, Gjertsen BT, Gilja OH, McCormack E. Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma. J Control Release. 2017; 245:70-80. Epub 20161118. doi: 10.1016/j.jconrel.2016.11.019. PubMed PMID: 27871988; https://www.ncbi.nlm.nih.gov/pubmed/27871988
Dimcevski G, Kotopoulis S, Bjanes T, Hoem D, Schjott J, Gjertsen BT, Biermann M, Molven A, Sorbye H, McCormack E, Postema M, Gilja OH. A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer. J Control Release. 2016; 243:172-81. Epub 20161012. doi: 10.1016/j.jconrel.2016.10.007. PubMed PMID: 27744037; https://www.ncbi.nlm.nih.gov/pubmed/27744037
Kotopoulis S, Delalande A, Popa M, Mamaeva V, Dimcevski G, Gilja OH, Postema M, Gjertsen BT, McCormack E. Sonoporation-enhanced chemotherapy significantly reduces primary tumour burden in an orthotopic pancreatic cancer xenograft. Mol Imaging Biol. 2014; 16(1):53-62. doi: 10.1007/s11307-013-0672-5. PubMed PMID: 23877869; https://www.ncbi.nlm.nih.gov/pubmed/23877869
McCormack E, Silden E, West RM, Pavlin T, Micklem DR, Lorens JB, Haug BE, Cooper ME, Gjertsen BT. Nitroreductase, a near-infrared reporter platform for in vivo time-domain optical imaging of metastatic cancer. Cancer Res. 2013; 73(4):1276-86. Epub 20121210. doi: 10.1158/0008-5472.CAN-12-2649. PubMed PMID: 23233739; https://www.ncbi.nlm.nih.gov/pubmed/23233739
Xenograft & Imaging Mass Cytometry Theranostics Pharmacology AML
Pharmacology
Gundersen ET, Forde JL, Tislevoll BS, Leitch C, Barratt G, Gjertsen BT, Herfindal L. Repurposing chlorpromazine for anti-leukaemic therapy by nanoparticle encapsulation. Int J Pharm. 2022; 612:121296. Epub 20211115. doi: 10.1016/j.ijpharm.2021.121296. PubMed PMID: 34793932; https://www.ncbi.nlm.nih.gov/pubmed/34793932
Malani D, Kumar A, Bruck O, Kontro M, Yadav B, Hellesøy M, Kuusanmaki H, Dufva O, Kankainen M, Eldfors S, Potdar S, Saarela J, Turunen L, Parsons A, Vastrik I, et al. Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discov. 2022; 12(2):388-401. Epub 20211117. doi: 10.1158/2159-8290.CD-21-0410. PubMed PMID: 34789538; https://www.ncbi.nlm.nih.gov/pubmed/34789538
Tadele DS, Robertson J, Crispin R, Herrera MC, Chlubnova M, Piechaczyk L, Ayuda-Duran P, Singh SK, Gedde-Dahl T, Floisand Y, Skavland J, Wesche J, Gjertsen BT, Enserink JM. A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation. J Biol Chem. 2021; 296:100179. Epub 20201217. doi: 10.1074/jbc.RA120.015285. PubMed PMID: 33303632; PubMed Central PMCID: PMC7948465; https://www.ncbi.nlm.nih.gov/pubmed/33303632
Alme E, Tornroos KW, Gjertsen BT, Bjorsvik HR. Synthesis of N-Aryl- and N-alkyl-Substituted Imidazolium Silver Complexes: Cytotoxic Screening by Using Human Cell Lines Modelling Acute Myeloid Leukaemia. ChemMedChem. 2020; 15(16):1509-14. Epub 20200709. doi: 10.1002/cmdc.202000138. PubMed PMID: 32558262; https://www.ncbi.nlm.nih.gov/pubmed/32558262
Bjorsvik HR, Gjertsen BT, Elumalai V. Hit to Leads with Cytotoxic Effect in Leukemic Cells: Total Synthesis Intermediates as a Molecule Treasure Chest. ChemMedChem. 2020; 15(10):862-70. Epub 20200421. doi: 10.1002/cmdc.202000066. PubMed PMID: 32233065; https://www.ncbi.nlm.nih.gov/pubmed/32233065
Kuusanmaki H, Leppa AM, Polonen P, Kontro M, Dufva O, Deb D, Yadav B, Bruck O, Kumar A, Everaus H, Gjertsen BT, Heinaniemi M, Porkka K, Mustjoki S, Heckman CA. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica. 2020; 105(3):708-20. Epub 20190711. doi: 10.3324/haematol.2018.214882. PubMed PMID: 31296572; PubMed Central PMCID: PMC7049363; https://www.ncbi.nlm.nih.gov/pubmed/31296572
Majumder MM, Leppa AM, Hellesøy M, Dowling P, Malyutina A, Kopperud R, Bazou D, Andersson E, Parsons A, Tang J, Kallioniemi O, Mustjoki S, O'Gorman P, Wennerberg K, Porkka K, et al. Multi-parametric single cell evaluation defines distinct drug responses in healthy hematologic cells that are retained in corresponding malignant cell types. Haematologica. 2020; 105(6):1527-38. Epub 20190822. doi: 10.3324/haematol.2019.217414. PubMed PMID: 31439679; PubMed Central PMCID: PMC7271564; https://www.ncbi.nlm.nih.gov/pubmed/31439679
Mercatelli D, Bortolotti M, Andresen V, Sulen A, Polito L, Gjertsen BT, Bolognesi A. Early Response to the Plant Toxin Stenodactylin in Acute Myeloid Leukemia Cells Involves Inflammatory and Apoptotic Signaling. Front Pharmacol. 2020; 11:630. Epub 20200508. doi: 10.3389/fphar.2020.00630. PubMed PMID: 32457623; PubMed Central PMCID: PMC7226368; https://www.ncbi.nlm.nih.gov/pubmed/32457623
Ladds M, Pastor-Fernández A, Popova G, van Leeuwen IMM, Eng KE, Drummond CJ, Johansson L, Svensson R, Westwood NJ, McCarthy AR, Tholander F, Popa M, Lane DP, McCormack E, McInerney GM, et al. Autophagic flux blockage by accumulation of weakly basic tenovins leads to elimination of B-Raf mutant tumour cells that survive vemurafenib. PLoS One. 2018; 13(4):e0195956. Epub 20180423. doi: 10.1371/journal.pone.0195956. PubMed PMID: 29684045; PubMed Central PMCID: PMC5912769; https://www.ncbi.nlm.nih.gov/pubmed/29684045
Ladds M, van Leeuwen IMM, Drummond CJ, Chu S, Healy AR, Popova G, Pastor Fernández A, Mollick T, Darekar S, Sedimbi SK, Nekulova M, Sachweh MCC, Campbell J, Higgins M, Tuck C, et al. A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage. Nat Commun. 2018; 9(1):1107. Epub 20180316. doi: 10.1038/s41467-018-03441-3. PubMed PMID: 29549331; PubMed Central PMCID: PMC5856786; https://www.ncbi.nlm.nih.gov/pubmed/29549331
Omsland M, Bruserud Ø, Gjertsen BT, Andresen V. Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-kappaB inhibition in acute myeloid leukemia (AML). Oncotarget. 2017; 8(5):7946-63. doi: 10.18632/oncotarget.13853. PubMed PMID: 27974700; PubMed Central PMCID: PMC5352373; https://www.ncbi.nlm.nih.gov/pubmed/27974700
Sandtorv AH, Leitch C, Bedringaas SL, Gjertsen BT, Bjorsvik HR. 4-Alkylated Silver-N-Heterocyclic Carbene (NHC) Complexes with Cytotoxic Effects in Leukemia Cells. ChemMedChem. 2015; 10(9):1522-7. Epub 20150806. doi: 10.1002/cmdc.201500234. PubMed PMID: 26250720; PubMed Central PMCID: PMC4576820; https://www.ncbi.nlm.nih.gov/pubmed/26250720
Haaland I, Opsahl JA, Berven FS, Reikvam H, Fredly HK, Haugse R, Thiede B, McCormack E, Lain S, Bruserud Ø, Gjertsen BT. Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Mol Cancer. 2014; 13:116. Epub 20140521. doi: 10.1186/1476-4598-13-116. PubMed PMID: 24885082; PubMed Central PMCID: PMC4032636; https://www.ncbi.nlm.nih.gov/pubmed/24885082
Fredly H, Gjertsen BT, Bruserud Ø. Histone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agents. Clin Epigenetics. 2013; 5(1):12. Epub 20130730. doi: 10.1186/1868-7083-5-12. PubMed PMID: 23898968; PubMed Central PMCID: PMC3733883; https://www.ncbi.nlm.nih.gov/pubmed/23898968
McCormack E, Haaland I, Venås G, Forthun RB, Huseby S, Gausdal G, Knappskog S, Micklem DR, Lorens JB, Bruserud Ø, Gjertsen BT. Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia. Leukemia. 2012; 26(5):910-7. Epub 20111108. doi: 10.1038/leu.2011.315. PubMed PMID: 22064349; https://www.ncbi.nlm.nih.gov/pubmed/22064349
Xenograft & Imaging Mass Cytometry Theranostics Pharmacology AML
AML
Forthun RB, Aasebo E, Rasinger JD, Bedringaas SL, Berven F, Selheim F, Bruserud Ø, Gjertsen BT. Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. J Proteomics. 2018; 173:32-41. Epub 20171121. doi: 10.1016/j.jprot.2017.11.014. PubMed PMID: 29175091; https://www.ncbi.nlm.nih.gov/pubmed/29175091
Nepstad I, Hatfield KJ, Aasebo E, Hernandez-Valladares M, Brenner AK, Bartaula-Brevik S, Berven F, Selheim F, Skavland J, Gjertsen BT, Reikvam H, Bruserud Ø. Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison. Expert Opin Ther Targets. 2018; 22(7):639-53. Epub 20180622. doi: 10.1080/14728222.2018.1487401. PubMed PMID: 29889583; https://www.ncbi.nlm.nih.gov/pubmed/29889583
Bruserud Ø, Reikvam H, Fredly H, Skavland J, Hagen KM, van Hoang TT, Brenner AK, Kadi A, Astori A, Gjertsen BT, Pendino F. Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. Oncotarget. 2015; 6(5):2794-811. doi: 10.18632/oncotarget.3056. PubMed PMID: 25605239; PubMed Central PMCID: PMC4413618; https://www.ncbi.nlm.nih.gov/pubmed/25605239
Li L, Osdal T, Ho Y, Chun S, McDonald T, Agarwal P, Lin A, Chu S, Qi J, Li L, Hsieh YT, Dos Santos C, Yuan H, Ha TQ, Popa M, et al. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell. 2014; 15(4):431-46. doi: 10.1016/j.stem.2014.08.001. PubMed PMID: 25280219; PubMed Central PMCID: PMC4305398; https://www.ncbi.nlm.nih.gov/pubmed/25280219
Skavland J, Jørgensen KM, Hadziavdic K, Hovland R, Jonassen I, Bruserud Ø, Gjertsen BT. Specific cellular signal-transduction responses to in vivo combination therapy with ATRA, valproic acid and theophylline in acute myeloid leukemia. Blood Cancer Journal. 2011; 1(2):e4. Epub 20110211. doi: 10.1038/bcj.2011.2. PubMed PMID: 22829110; PubMed Central PMCID: PMC3255270; https://www.ncbi.nlm.nih.gov/pubmed/22829110